On 3 November, IPG Photonics reported third-quarter 2026 results (for the quarter ended 30 September 2026): revenue of $287.5 million, up about 15% year over year, the fourth consecutive quarter of double-digit year-over-year growth; GAAP net income of $20.3 million, or $0.47 per diluted share (versus $0.18 a year earlier); adjusted EPS of $0.61 and adjusted EBITDA of $51.5 million, up 39% year over year. By segment, industrial solutions revenue was $239.5 million, up 12% year over year, with welding the principal driver; advanced solutions revenue was $48.0 million, up 33% year over year, with semiconductor laser revenue more than doubling. The company guides fourth-quarter revenue at $265–295 million and expects to close its acquisition of Lumibird Medical in the fourth quarter.
01 / The numbers: $287.5 million, with profit recovering faster than revenue
In the third quarter (ended 30 September 2026), IPG’s revenue was $287.5 million, up 14.6% (about 15%) year over year, above the prior quarter’s $278.6 million and above a consensus of about $283.3 million. GAAP net income was $20.3 million, or $0.47 per diluted share, well above the $7.5 million and $0.18 of a year earlier; adjusted net income was $26.3 million, adjusted EPS $0.61, above the prior year’s $0.35 and a consensus of about $0.49; adjusted EBITDA was $51.5 million, up 39% year over year.
Gross margin improved too: GAAP gross margin of 40.7%, versus 39.5% a year earlier, and adjusted gross margin of 41.0%. One detail deserves precision, though: the margin improvement includes about $5 million of net tariff refunds, worth roughly 170 basis points — so excluding that one-off item, adjusted gross margin was about 39.3%. The profit recovery is real, but part of it comes from a policy refund rather than operations alone, and the two should be kept apart when reading the report.
02 / The mix: welding leads industrial, semiconductors and defence lift advanced solutions
By segment, industrial solutions revenue was $239.5 million, up 12% year over year. Management said on the call that welding is now the principal application driving industrial growth, benefiting from advanced battery manufacturing for electric vehicles and stationary energy storage; additive manufacturing also contributed; cutting remains part of the business but accounted for less than 20% of total revenue last year, and management does not expect meaningful growth in cutting, while pointing to opportunities in 2027 and 2028; cleaning grew as well, with marking and engraving named as potential growth areas.
Advanced solutions revenue was $48.0 million, up 33% year over year — the faster-growing pole. Semiconductor laser revenue more than doubled year over year, driven by increased investment in process technologies for GPUs, high-performance computing and high-bandwidth memory, with the company citing qualifications with a number of top-tier wafer-fabrication-equipment suppliers for next-generation lithography, metrology and inspection tools. In defence, the majority of CROSSBOW counter-drone laser system shipments to Lockheed Martin are complete, with the remainder expected in the fourth quarter; the company also introduced the CROSSBOW SE, with longer range and coverage of larger drones. By region, North America grew 33% year over year, Asia 14%, and Europe fell 1%.
03 / The outlook: narrower Q4 guidance, and a medical acquisition as the next piece
For the fourth quarter, the company guides revenue of $265–295 million, adjusted EPS of $0.30–$0.60 and adjusted EBITDA of $33–50 million, with no assumed Lumibird contribution. Notably, the guidance midpoint (about $280 million) sits below third-quarter actual revenue, and management pointed on the call to moderating battery-capacity additions in China as one reason — a signal worth tracking, since battery demand is one of welding growth’s engines and it appears to be shifting gear.
The other piece is medical: the company expects to close its €300 million acquisition of Lumibird Medical in the fourth quarter. Management says this will expand its medical addressable market to more than $2 billion and is expected to add to earnings per share in 2027. That remains a company expectation — the deal has not closed, and synergies and earnings contribution will need to be verified in post-closing reports. The company also plans an investor day on 2 March 2027 to present its strategy and long-term financial targets, which will offer a further checkpoint.
PRIMARY REFERENCES & LINKS
- IPG Photonics Reports $287.5M in Quarterly Revenue Ahead of Lumibird Medical Deal Close
Read in full: revenue of $287.5 million, industrial and advanced growth rates, the welding and semiconductor descriptions, CROSSBOW delivery progress, regional growth and fourth-quarter revenue guidance all come from this report; the report is dated 4 November, but the results-release event date is 3 November, which is the date used here.
Open source link ↗ - IPG Photonics Q3 2026 Earnings Call Transcript
Used to cross-check segment revenue (industrial $239.5 million, advanced $48.0 million), gross margins (GAAP 40.7%, adjusted 41.0%, including $5 million of tariff refunds), adjusted EBITDA of $51.5 million, full fourth-quarter guidance (revenue, adjusted EPS, adjusted EBITDA) and the Lumibird Medical statements.
Open source link ↗
